.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,227,454

« Back to Dashboard

Details for Patent: 8,227,454

Title:Estrogenic compounds, pharmaceutical compositions and formulations comprising the same
Abstract: Novel estrogenic compounds of Formula I are provided. ##STR00001## wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R.sub.1 does not exist; R.sub.2 is lower alkyl; R.sub.3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R.sub.4 through R.sub.13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R.sub.14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R.sub.1 is hydroxy, the hydroxy or ester substituent may have either an .alpha. or a .beta. orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
Inventor(s): Hill; Edward N. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Duramed Pharmaceuticals, Inc. (Cincinnati, OH)
Filing Date:Jun 23, 2011
Application Number:13/167,350
Claims:1. A pharmaceutical composition incorporating a compound represented by the following formula: ##STR00008## or pharmaceutically acceptable salts thereof, wherein: the bond represented by a wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is selected from the group consisting of hydrogen, sulfate and glucuronide, and when the wavy line is a double bond, R.sub.1 does not exist; R.sub.2 and R.sub.3 is selected from the group consisting of hydrogen, sulfate and glucuronide; and said compound being present in a chemically pure form.

2. The pharmaceutical composition of claim 1, wherein the compound has the following characteristics: having a peak located at about 1.2 ppm on a .sup.1H-NMR; and having a peak located at about 45 ppm on a .sup.13C-NMR.

3. The pharmaceutical composition of claim 1, wherein said compound is greater than 95% pure.

4. The pharmaceutical composition of claim 1, wherein when R.sub.1 is hydrogen, the compound has a .beta. orientation at the C17 position.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt thereof is selected from the group consisting of a sodium salt, a calcium salt, a magnesium salt, a lithium salt and an amine salt.

6. The pharmaceutical composition of claim 1, wherein the composition further comprises at least one additionally pharmaceutically active ingredient.

7. The pharmaceutical composition of claim 6, wherein the at least one additional pharmaceutically active ingredient is selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts and vitamin D, and mixtures and combinations thereof.

8. The pharmaceutical composition of claim 1, wherein the compound is represented by the following formula: ##STR00009##

9. The pharmaceutical composition of claim 8, wherein said compound is greater than 95% pure.

10. The pharmaceutical composition of claim 8, wherein the composition further comprises at least one additionally pharmaceutically active ingredient.

11. The pharmaceutical composition of claim 10, wherein the at least one additional pharmaceutically active ingredient is selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts and vitamin D, and mixtures and combinations thereof.

12. A topical pharmaceutical formulation comprising: (a) a compound represented by the following formula: ##STR00010## or pharmaceutically acceptable salts thereof, wherein: the bond represented by a wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is selected from the group consisting of hydrogen, sulfate and glucuronide, and when the wavy line is a double bond, R.sub.1 does not exist; R.sub.2 and R.sub.3 is selected from the group consisting of hydrogen, sulfate and glucuronide; said compound being present in a chemically pure form; and (b) a pharmaceutically active ingredient is selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts and vitamin D, and mixtures and combinations thereof.

13. The topical pharmaceutical formulation of claim 12, wherein the formulation is a vaginal cream.

14. The topical pharmaceutical formulation of claim 12, wherein the formulation is a gel.

15. The topical pharmaceutical formulation of claim 12, wherein the formulation is a suppository.

16. The topical pharmaceutical formulation of claim 12, wherein the formulation is a transdermal patch.

17. The topical pharmaceutical formulation of claim 12, wherein the compound is represented by the following formula: ##STR00011## or pharmaceutically acceptable salts thereof, wherein the bond represented by a wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is H and when the wavy line is a double bond, R.sub.1 does not exist.

18. The topical pharmaceutical formulation of claim 12, wherein the compound is represented by the following formula: ##STR00012## or pharmaceutically acceptable salts thereof, wherein the bond represented by a wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is H and when the wavy line is a double bond, R.sub.1 does not exist.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc